 |
New data adds to a growing body of evidence that as well as saving lives, treating HIV can also help prevent HIV transmission, making the scale-up of treatment all the more urgent. In May 2011, a study called HPTN 052 supported by the US National Institutes of Health found a 96% reduction in transmission when HIV-positive persons in a relationship with an HIV-negative person were started early on antiretroviral therapy compared to people whose treatment was deferred.9 Early treatment also significantly reduced the development of tuberculosis, which remains the number one killer of people living with HIV/AIDS. Download this publication |
 |
Now is a critical time to ensure widest possible access to ART: a landmark scientific breakthrough in 2011 showed that treatment with antiretroviral medicines (ARVs) not only saves lives, but can also stop HIV from being transmitted by up to 96%.4 In response to this evidence, in 2012 the World Health Organization (WHO) issued guidance supporting immediate treatment – regardless of a person’s immune system’s status or CD4 count – for HIV-positive people who have HIV-negative partners, in order to help prevent transmission of the virus.5 At the same time, guidance was also issued suggesting the possibility of offering full antiretroviral therapy for life to all pregnant women living with HIV for prevention of mother-to-child transmission of the virus (PMTCT). Download this publication |
 |
The aim of this update is to provide information and guidance to countries on how best to use tenofovir (TDF) for the treatment of children with HIV. It is intended to complement the World Health Organization (WHO) normative guidelines on antiretroviral therapy (ART) and also support the goal of increasing access to simpler paediatric antiretroviral (ARV) formulations, in line with Treatment 2.0. Download this publication |
 |
This document is a discussion paper, prepared for the 2012 InternationalAIDS Conference in Washington DC, United States of America. It highlights key issues that confront the global community, policy-makers and national programme planners as they seek to make optimal use of antiretroviral drugs (ARVs) as part of the broader response to HIV. It also discusses how ARVs could contribute to eventually ending the HIV epidemic. The paper does not in itself constitute a World Health Organization (WHO) guidance document, even though it summarizes existing WHO guidelines related to ARV use, highlights progress in the Treatment 2.0 initiative, and summarizes the next steps in WHO’s normative work related to ARV use. Download this publication |
 |
Globally, an estimated 17 million women and girls are living with HIV, and more than two million pregnancies occur amongst HIV-positive women each year. In 2009, an estimated 370,000 children acquired HIV. While the total number of children being born with HIV has decreased due to the increased access to services that support women living with HIV to have HIV-free babies (usually referred to as prevention of mother-to-child transmission to PMTCT), the majority of remaining cases occur in resource-poor nations. Download this publication |
 |
The document outlines how UNAIDS and WHO will work with partner organizations to accelerate global efforts to scale up treatment towards sustained universal access, optimizing both HIV specific and broader health outcomes, including maximizing the HIV and TB preventive benefits of ART. It reflects the need for innovation, for efficiency gains, for shifts in how programmes are financed and delivered, and for additional investments up front that will ultimately reduce costs in the medium and long-term. Download this publication |
 |
The meeting was part of WHO’s commitment to the broader Treatment 2.0 initiative, coordinated by the UNAIDS Secretariat and WHO, which aims to radically simplify all aspects of quality HIV treatment, including drugs, diagnostics and healthcare delivery systems, to reduce costs and to mobilize communities towards greater engagement in programme design and implementation in resource-limited settings. Treatment 2.0 focuses on short– (1-3 years), medium– (4-6 years), and long– (7-10 years) term objectives to achieve and sustain universal access to treatment for all who need it and maximize the preventive benefits of treatment. Download this publication |
 |
HIV Testing & Treatment as Prevention in China Download this publication |
 |
In 2005, the predecessor of this Committee, Scientific Committee on AIDS, published its set of recommended principles of antiretroviral therapy to provide general guidance for the use of antiretrovirals in Hong Kong. The document stated nine major principles of antiretroviral use. Download this publication |
